With 2 CAR-T therapies striving for global approval, and a 3rd contender from Bristol-Myers Squibb closing in on the finish line of the race to market, the CAR-TCR field continues to boom with excitement as the competition begins to heat back up.
It is well known that the current approved therapies have encountered some difficulties, specifically around their pricing and uptake in hospitals due to expensive manufacturing processes. Lots of work needs to be done in this space to reduce cost of goods and improve turnaround time to decrease the overall price of these therapies, improving their accessibility for patients globally.
These challenges in turn push the need for ground-breaking work in this space, from discovery through to commercialization, which is what the CAR-TCR Summit promises to showcase this September.
Time: 09:00 to 17:00
(Drug Developer Pricing) Conference + Focus Day + (Workshop Day or Bootcamp): USD 5297.00,
(Drug Developer Pricing) Conference + Focus Day: USD 4298.00,
(Drug Developer Pricing) Conference + (Workshop Day or Bootcamp): USD 4298.00,
(Drug Developer Pricing) Conference Only: USD 3099.00
(Drug Developer Pricing) Intro to CAR-TCR Bootcamp: USD 1299.00,
(Standard Pricing) Conference + Focus Day + (Workshop Day or Bootcamp): USD 6497.00,
(Standard Pricing) Conference + Focus Day: USD 5498.00,
(Standard Pricing) Conference + (Workshop Day or Bootcamp): USD 5498.00,
(Standard Pricing) Conference Only: USD 4299.00,
(Standard Pricing) Intro to CAR-TCR Bootcamp: USD 1799.00
Speakers: Sanjay Srivastava, Accenture, Robin Goodreau, Access Biologicals, Erica Elefant, Adaptimmune, Stewart Abbott, Adicet Bio, Paul Rennert, Aleta Biotherapeutics, Janet Lynch Lambert, Alliance for Regenerative Medicine, Michael Werner, Alliance Regenerative Medicine, Siler Panowski, Solid Tumors Allogene, Faraz Zaman, Amgen, Blake Aftab, Atara Biotherapeutics, Kristin Yarema, Atara Biotherapeutics, Pippa Gledhill, Beacon Targeted Therapies, Mark Flower, Be The Match BioTherapies, Mark White, Berkeley Lights, Inc, Hassan Saleem, bluebird bio, Peter Olagunju, bluebird bio, Rena Conti, Boston University, Katie Newhall, Bristol-Myers Squibb, Samik Basu, Cabaletta Bio, Travis Young, Calibr, Steven Kanner, Caribou Biosciences, Michael Klichinsky, Carisma Therapeutics, Michael Singer, Cartesian Therapeutics, Julianne Smith, Cellectis, William Monteith, Cellectis, Sebastian Warth, CellGenix, Elena Spanjaard, Celyad, Peggy Sotiropoulou, Celyad, Adrienne Farid, Century Therapeutics, Osvaldo (Lalo) Flores, Century Therapeutics, Thierry Nguyen, Century Therapeutics, Saul Priceman, City of Hope, Mark Sawicki, Cryoport, Rick Morgan, Editas Medicine, Bob Valamehr, Fate Therapeutics, Raedun Clarke, Fate Therapeutics, Peter Marks, FDA, Alice Brown, GammaDelta Therapeutics, Delfi Krishna, GlaxoSmithKline, Michael DeRidder, GlaxoSmithKline, Wei (William) Cao, Gracell Biotechnologies, Roman Yelensky, Gritstone Oncology, Dominic Clarke, HemaCare, David Smith, Hitachi Chemical Advanced Therapeutics Solutions, Cameron Durrant, Humanigen, Andrew Hobbs, Huron, Santanu Das, Huron, Martin Lachs, ICON, Ali Mohamed, Immatics, Steffen Walter, Immatics, Yannick Bulliard, Immatics, Lawrence Lamb, Incysus Therapeutics, Maria Fardis, Iovance, Sean Mackay, Isoplexis, David Fontana, Juno Therapeutics a Bristol-Myers Squibb Company, Don Healey, KBI Biopharma, Adrian Bot, Kite, a Gilead Company, John Rossi, Kite, a Gilead Company, Tam Soden, Kite, a Gilead Company, Peter Emtage, Kite, a Gilead Company, John Tomtishen, Legend Biotech, Eytan Abraham, Lonza Pharma and Biotech, Minh Hong, Lonza Pharma and Biotech, Rogier Reijmers, Lumicks, Madhusudan Peshwa, Mana Therapeutics, Jean-François Chaubard, MaSTherCell, Allison Matthews, Mayo Clinic, Nancy Pick, Mayo Clinic, Dolores Schendel, Medigene, Isabelle Riviere, Memorial Sloan-Kettering Cancer Center, Prasad Adusumilli, Memorial Sloan-Kettering Cancer Center, Ravi Kapur, MicroMedicine, Ian Guadet, Miltenyi Biotec, Cynthia Bamdad, Minerva Bio, Mark Trusheim, MIT Center for Biomedical Innovation, Luca Alberici, MolMed, Knut Niss, Mustang Bio, Hans Klingemann, NantKwest, Mario Marcondes, Nektar Therapeutics, Guanglin Yu, Novartis, Ian Miller, Novartis, Simon Briggs, Novartis, Stefan Hendriks, Novartis, Charles Mooney, Oklahoma Blood Institute, Steve Shamah, Obsidian Therapeutics, Stefanie Mandl, PACT Pharma, Mo Heidaran, Parexel International, Devon Shedlock, Poseida Therapeutics, Joanne McCaigue, Poseida Therapeutics, Matthew Spear, Poseida Therapeutics, Chris Heery, Precision BioSciences, Megan Liles, Precision for Medicine Oncology and Rare Disease, Vita Golubovskaya, Promab Biotechnologies, Jey Cheng, Promega, Kent Thorup, QuickSTAT, Franco Marincola, Refuge Biotech, Christina Coughlin, Rubius Therapeutics, Laurence Turka, Rubius Therapeutics, Spencer Fisk, Rubius Therapeutics, Jason Fontenot, Sangamo Therapeutics, Thor Wagner, Seattle Children’s Hospital, Alison Holzer-Speed, Stanford School of Medicine, Steven Feldman, Stanford School of Medicine, Qiong Xue, Takeda, Robert Hofmeister, TCR2, Deepu Madduri, The Mount Sinai Hospital, Timothy Sharp, TMRW, Ana Radeljevic, Torque Therapeutics, Shon Green, Umoja Biopharma, Scott Kitchen, UCLA, Clint Divine, University of Kansas Medical Center, Erin Winters, University of Kansas Medical Center, Joseph McGuirk, University of Kansas Medical Center, Allison Hubel, University of Minnesota, Avery Posey, University of Pennsylvania, Bruce Levine, University of Pennsylvania, Carl June, University of Pennsylvania, Jonathan Epstein, University of Pennsylvania, Nicole Aqui, University of Pennsylvania, Robert Richards, University of Pennsylvania, Marko Radic, University of Tennessee, Frank OLoughlin, Werum, Frank OLoughlin, Werum, Bernadette Bourjolly, ZS Associates, Maria Whitman, ZS Associates